From the fact that sSortilin/NTSR3 is released by mechanisms similar to those leading to EGFR ligands and that in numerous cancer cell systems NT signaling depends on EGFR activation [34,35], the verification that sSortilin/NTSR3 and EGF could be competitive ligands has been made. The gene discussed is EGFR; the disease is cancer.